Wang, Yudong <br/><br/>
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.  [electronic resource] 

 -  Scientific reports  02 2020 
 - 3080 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-2322 
<br/><br/><label>Standard No.: </label>10.1038/s41598-020-58366-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Angiogenesis Inhibitors--adverse effects<br/>Boron Compounds--adverse effects<br/>Glycine--adverse effects<br/>Humans<br/>Indazoles<br/>Kaplan-Meier Estimate<br/>Middle Aged<br/>Mutation--genetics<br/>Neoplasms--drug therapy<br/>Progression-Free Survival<br/>Pyrimidines--adverse effects<br/>Sulfonamides--adverse effects<br/>Treatment Outcome<br/>Tumor Suppressor Protein p53--genetics<br/>Vorinostat--adverse effects<br/>Young Adult